Immuron Limited

Buy Online

Protectyn®

Protectyn® is a very special form of colostrum that is naturally boosted with antibodies and other components to protect infants from diseases of the digestive system....

Travelan®

Travelan® is an over-the-counter oral polyclonal antibody therapy that helps reduce the risk of Travellers’ Diarrhoea when you are travelling overseas....

The Watchlist: Immuron's Travelan sales growth, clinical pipeline achievements and upcoming milestones!

26 April 2024

CEO Steve Lydeamore provides an update on Travelan's exponential growth!...

Immuron marks surge in Travelan® sales on eve of entry into US via Walmart.com

10 April 2024

Immuron Ltd (NASDAQ:IMRN, ASX:IMC), a biopharmaceutical company headquartered in Australia, says sal...

Guarding Gut Health on the Go: The Travelan® Advantage

10 April 2024

The Not Old Better Show, Art of Living Interview Series. Today's episode takes us on a fascinati...

Clinical data imminent!

6 February 2024

Immuron CEO Steve Lydeamore speaks about the clinical work it is doing with IMM-124e and IMM-529, it...

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.

The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.

Payment Options

Contact Information

Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Phone: +613 8892 4854
Fax: +613 9899 8533

Travelan®

Protectyn®

Record half yearly Travelan® sales

Buy Online

Protectyn®

Travelan®

Clinical Insights & Updates

Travelan® clinical study resulting in up to 90% efficacy in prevention of travelers’ diarrhea

IMM-529 pre-clinical study indicates protection against C.diff infection and disease recurrence

Immuron poster presentation at Military Health System Research Symposium 2023

Recent Articles

The Watchlist: Immuron's Travelan sales growth, clinical pipeline achievements and upcoming milestones!

Immuron marks surge in Travelan® sales on eve of entry into US via Walmart.com

Guarding Gut Health on the Go: The Travelan® Advantage

Clinical data imminent!

Partners

Secure Shopping

Get Connected

About Us

Information

Payment Options

Contact Information